Day 4 Program

Poster Session 5

Day 4: December 12, 2025

12:30 PM–2:00 PM CST

Exhibit Hall

Session Details

The text of the abstracts will be posted on Monday, November 24.

PS5-01-01

Concordance of genomic alterations between paired tissue (T) and plasma (P) samples analyzed with next generation sequencing (NGS) panels from patients (pts) with HER2-positive metastatic breast cancer (mBC)

Santiago Escrivá-de-Romaní, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

PS5-01-02

Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer: long-term survival results from the phase 3 PHILA study

Binghe Xu, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

PS5-01-03

Jbcrg-m06/emerald post-hoc analysis by physician’s choice of docetaxel or paclitaxel: efficacy and safety of eribulin mesylate vs taxanes combined with trastuzumab and pertuzumab as first-line for her2-positive locally advanced or metastatic breast cancer

Norikazu Masuda, Graduate School of Medicine, Kyoto University, Kyoto, Japan

PS5-01-04

Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer Results from the AGMT_MBC-Registry

Gabriel Rinnerthaler, Medical University Graz, Graz, Austria

PS5-01-05

Unraveling KAdcyla (Trastuzumab emtansine; T-DM1) resistance in HER2+ advanced breast cancer geicam/2017-04-KATIA study: biomarker analyses

Jose Ángel García-Sáenz, Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC); CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Madrid, Spain

PS5-01-06

Contribution of Sociodemographic Characteristics to Treatment Delays in Patients with de novo Metastatic HER2-Positive Breast Cancer

Apoorva Ravichandran, University of Chicago Medicine, Chicago, IL

PS5-01-08

Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THP

Rodrigo Sanchez-Bayona, Hospital Universitario 12 de Octubre. Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

PS5-01-09

Proactive Brain Screening using contrast-enhanced (CE) brain CT scans in HER2+ metastatic Breast Cancer (mBC)

Gaia Griguolo, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

PS5-01-10

Estimating the effect of initiating early maintenance endocrine therapy on brain metastases-free survival and other clinical outcomes in patients with HER2+/HR+ mBC without brain metastases: A target trial emulation

Thibaut Sanglier, F. Hoffmann-La Roche Ltd, Basel, Switzerland

PS5-01-11

Impact of antiemetic strategy on overall survival in patients with metastatic HER2-positive breast cancer treated with trastuzumab deruxtecan: A real-world retrospective study

Sowjanya Reganti, Cancer Care Specialists, Reno, NV

PS5-01-12

Real-world time to next treatment in HER2+ breast cancer patients with brain metastases: trastuzumab deruxtecan vs tucatinib based therapy as second-line treatment

Vikram Gorantla, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA

PS5-01-13

Utidelone plus bevacizumab for the treatment of HER2-positive breast cancer brain metastases (U-BOMB-HER): A multicenter, single-arm phase IIstudy

Min Yan, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

PS5-01-14

Trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd + pertuzumab in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): final results from DESTINY-Breast07

Fabrice André, Gustave Roussy, Paris-Saclay University, Villejuif, France

PS5-01-15

Real-world effectiveness of trastuzumab deruxtecan in HER2+ metastatic breast cancer by racial and ethnic group – Data from US community practices

Ruchit Shah, Daiichi Sankyo, Inc., Basking Ridge, NJ

PS5-01-16

Phase II Trial of the FASN Inhibitor, Denifanstat (TVB-2640), Plus Trastuzumab in Combination with Paclitaxel or Endocrine Therapy (ET) in Patients with HER2+ Metastatic Breast Cancer (MBC) Resistant to Trastuzumab

Tufia C Haddad, Mayo Clinic, Rochester, MN

PS5-01-17

Dna-based HER2 vaccine induces broader and more durable t-cell responses than peptide vaccine in advanced HER2-positive breast cancer

Ying Liu, University of Washington, Seattle, WA

PS5-01-18

Dalpiciclib Plus Pyrotinib Plus Letrozole for Patients with Estrogen Receptor-Positive and HER2-Positive Metastatic Breast Cancer (DAPLET)

Zhanhong Chen, Zhejiang Cancer Hospital, Hangzhou, China

PS5-01-19

Mechanisms of resistance to anti-HER2 therapies in brain metastatic derivatives of inflammatory HER2-positive breast cancer models

Caroline M. Sabotta, Baylor College of Medicine, Houston, TX

PS5-01-20

Taxane induction before trastuzumab-endocrine therapy improves 10-year survival in ER-positive HER2-positive metastatic breast cancer: a propensity-matched real-world analysis of 646 patients

Ahmed Elkhanany, Baylor College of Medicine, Houston, TX

PS5-01-21

Prognostic Significance of Circulating Tumor Cell Subtypes in HER2+ Metastatic Breast Cancer with Central Nervous System Metastases

Diana Jaber, McGaw Medical Center of Northwestern University, Chicago, IL

PS5-01-22

Efficacy of second- or third-line Tucatinib, Trastuzumab, and Capecitabine (TTC) following trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer: A multicenter French cohort study.

Jean Sebastien Frenel, Institut de Cancerologie de L'Ouest, Saint-Herblain, France

PS5-01-23

Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THP

Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

PS5-01-24

Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial

PAULA R POHLMANN, University of Texas MD Anderson Cancer Center, Houston, TX

PS5-01-25

Long-term response Patterns in HER2-positive advanced breast cancer within the geicam/2014-03 (registem) study

Isabel Alvarez, Unidad de Cáncer de Guipúzcoa – Osakidetza; GEICAM Spanish Breast Cancer Group, San Sebastián, Spain

PS5-01-26

Long-term outcomes of first-line (1L), guideline-recommended treatment versus alternative regimens in HER2+ metastatic breast cancer (mBC): a retrospective observational study of US electronic health records

Maki Inoue-Choi, AstraZeneca, Gaithersburg, MD

PS5-01-27

Outcomes by hormone receptor (HR) status in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with brain metastases (BM) treated with trastuzumab deruxtecan (T-DXd): a post-hoc subgroup analysis of DESTINY-Breast12

Hans Wildiers, University Hospitals Leuven, KU Leuven, Leuven, Belgium

PS5-01-28

Us real-world clinical outcomes of tucatinib, trastuzumab, and capecitabine following trastuzumab deruxtecan for the treatment of her2+ metastatic breast cancer

Jo Chien, UCSF, San Francisco, CA

PS5-01-30

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T‑DM1) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): Final analysis from DESTINY-Breast03

Seock-Ah Im, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of

PS5-02-01

Efficacy of cross-line therapy with anti-HER2 TKI in HER2-positive MBC: a multicenter real-world study

Ruixia Song, Chinese Academy of Medical Sciences and Peking Union Medical College – National Cancer Center, Cancer Hospital, Beijing, China

PS5-02-02

Early use of CDK4/6 inhibitor combined with endocrine therapy plus anti-HER2 antibody may get more survival benefit in HR+/HER2+ advanced breast cancer: result from a phase II single-arm mini cohort study (CABC016)

Yaxin Liu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China

PS5-02-03

Clinical Outcomes of Trastuzumab Emtansine (T-DM1) Following Trastuzumab Deruxtecan (T-DXd) in Metastatic Breast Cancer: A Single-Center Experience

Vicente Valero, MD ANDERSON CANCER CENTER, HOUSTON, TX

PS5-02-04

Incidence of the development of brain metastases in patients with advanced stage HER2+ breast cancer who have previously received a HER2 directed cancer vaccine.

Ying Liu, University of Washington, Seattle, WA

PS5-02-06

Is genetic testing of Her2-negative metastatic breast cancer patients implemented into clinical practice?

Georg Pfeiler, Medical University of Vienna, Vienna, Austria

PS5-02-07

Her2-overexpressing circulating tumor cells in patients treated by trastuzumab deruxtecan for metastatic her2+ breast cancer: clinical and prognostic implications

William Jacot, Institut du Cancer de Montpellier, Montpellier, France

PS5-02-08

Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

Seyda Gunduz, Koc University School of Medicine, Istanbul, Turkey

PS5-02-09

Unconjugated MMAE Pharmacokinetics in Combination with Tucatinib in Patients with HER2 Expressing Locally Advanced or Metastatic Breast and Gastric Cancer

Andrew SyBing, Pfizer, San Diego, CA

PS5-02-10

Pyrotinib plus capecitabine with or withoutradiotherapyin patients with HER2-positive metastatic breast cancer and brain metastases: Amulticenter, retrospective-prospective, real-world study in China (Post-PERMEATE)

Min Yan, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

PS5-02-11

Staying Ahead of Resistance: ctDNA-Guided Camizestrant Switching in HR+ Breast Cancer (SERENA-6)

Chiugo Okoye, Northeast Georgia Medical Center, Gainesville, GA

PS5-02-12

Intracranial Activity and Systemic Efficacy of Trastuzumab Deruxtecan in Breast Cancer Patients with Brain Metastases

Zouina Sarfraz, Miami Cancer Institute, Baptist Health South Florida, Miami, FL

PS5-02-13

Journeying Through the Spectrum of HER2 Expression Breast Cancer Clinic: Education Outcomes on Guiding Treatment Decisions​​

Tariqa Ackbarali, Medlive, Lake Worth, MA

PS5-02-14

“longterm” – long-term response (>18 months) in metastatic her2-positive breast cancer: a retrospective analysis of patients diagnosed between 2010 and 2020 in the german bngo network

Georg Erich Wilhelm Heinrich, Practice for gynecological oncology, Fürstenwalde, Germany

PS5-02-15

Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2- positive and HER2-low Metastatic Breast Cancer: Assessing the efficacy

Jihane BOUZIANE, CHU HASSAN II , Fez, Morocco, Fez, Morocco

PS5-02-16

Clinical outcomes and treatment attrition rates of HER2 positive metastatic breast cancer (MBC) patients at a tertiary referral cancer centre in London: the Guy’s Cancer experience.

Haixi Yan, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

PS5-02-18

Soluble E-cadherin-STAT3/NFκB axis in inflammatory breast cancer progression

Kiros Haddish Tesfamariam, MD Anderson Cancer Center, Houston, TX

PS5-02-19

Impact of HER2 kinase domain mutations on trastuzumab deruxtecan efficacy in HER2 low metastatic breast cancer

Yoshiya Horimoto, Tokyo Medical University, Tokyo, Japan

PS5-02-20

Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data

Milos Holanek, Masaryk Memorial Cancer Institute, and Faculty of Medicine, Masaryk University, Brno, Czech Republic

PS5-02-21

Chronic stress promotes brain metastasis via serotonin-HTR2B axis in triple-negative breast cancer: insights from spatial transcriptomic and functional analysis

Ju Young Ahn, Houston Methodist, Houston, TX

PS5-02-22

Impact of overall survival on the use of prophylactic granulocyte colony-stimulating factor with sacituzumab govitecan-hziy in the treatment of triple negative metastatic breast cancer patients

Fred Kudrik, South Carolina Oncology Associates, Columbia, SC

PS5-02-23

Aretha trial: Safety run-in results of eribulin + evexomostat in metastatic triple-negative breast cancer with metabolic dysfunction

Sherry Shen, Memorial Sloan Kettering Cancer Center, New York, NY

PS5-02-24

A randomized phase II study of pembrolizumab plus carboplatin vs. carboplatin alone in unresectable advanced breast cancer with chest wall disease (ICI-CHEST, TBCRC 44)

Neelima Vidula, Massachusetts General Hospital, Harvard Medical School, Boston, MA

PS5-02-25

Homologous Recombination Deficiency is the major determinant of response of Triple-Negative Breast Cancer to Cisplatin+Radiotherapy

Simon N Powell, memorial sloan kettering cancer center, New York, NY

PS5-02-26

A phase I/II, single arm, non-randomized study of ribociclib, a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor inhibitor, in advanced AR-positive triple-negative breast cancer: A Big Ten Cancer Research Consortium Study

Julia Knight-Shefner, University of Wisconsin Carbone Cancer Center, Madison, WI

PS5-02-27

Variations in lines of treatment and clinical outcomes in US health system patients with locally advanced, inoperable or metastatic triple negative breast cancer (la/m TNBC)

Yuanhui Zhang, Gilead Sciences, Inc, Foster City, CA

PS5-02-28

Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)

Kevin Kalinsky, Winship Cancer Institute, Emory University, Atlanta, GA

PS5-02-29

Clinical data of DB-1305/BNT325 (TROP2 antibody-drug conjugate [ADC]) in patients (pts) with metastatic triple negative breast cancer (mTNBC): Efficacy and safety data from a phase 1/2 trial

Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

PS5-02-30

Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

Milana V Dolezal, Stanford University School of Medicine, Stanford, CA

PS5-03-01

Phase I Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases

Kamran A Ahmed, Moffitt Cancer Center, Tampa, FL

PS5-03-02

Specific site of metastasis in stage IV triple-negative breast cancer: a national registry analysis of survival outcomes and treatment patterns

Shawn M Doss, Medical College of Georgia, Augusta, GA

PS5-03-03

Trop2-directed antibody-drug conjugate shr-a1921 combined with pd-l1 inhibitor adebrelimab for patients with advanced triple negative breast cancer: results from a phase 2, multi-cohort, open-label, non-controlled trial

Tao Wang, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

PS5-03-04

Timing of final oncologist visit and systemic treatment use near the end of life in advanced triple-negative breast cancer: a multinational cohort study

Milos Holanek, Masaryk Memorial Cancer Institute, and Faculty of Medicine, Masaryk University, Brno, Czech Republic

PS5-03-06

Real-world progression-free survival from first-line treatment initiation in patients with PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States

Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY

PS5-03-07

A Real-World Study on the Current Status of First-Line Treatment and Clinical Outcomes in Patients with Advanced Triple-Negative Breast Cancer (aTNBC) in Western China

Ting Luo, West China Hospital, Sichuan University, China, Chengdu, China

PS5-03-08

Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use

Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

PS5-03-09

Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01)

Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

PS5-03-10

Btg2 suppresses the invasion and metastasis of triple-negative breast cancer by inhibiting the ubiquitination-mediated degradation of becn1

Hui Hui Li, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, China

PS5-03-11

Combinatorial EZH2 Inhibition and Dopamine D1 Agonism Suppresses Pro-Inflammatory Monocytes and TNBC Tumor Progression

Eswar Shankar, The Ohio State University, columbus, OH

PS5-03-12

Real-world BRCA and PD-L1 testing among first-line triple negative metastatic breast cancer patients

Fred Kudrik, South Carolina Oncology Associates, Columbia, SC

PS5-03-13

Combinatory inhibition of Aurora Kinases and EZH2 leads to a synergistic antitumor effect in Triple Negative Breast Cancer

Jia Xu, University of Alabama at Birmingham, Birmingham, AL

PS5-03-14

Clinical features and drug-drug interactions of patients treated with Sacituzumab Govitecan for metastatic triple-negative breast cancer: a multicenter correlative real-world updated analysis

Claudia Martinelli, Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale", Naples, Italy

PS5-03-15

Real-world outcomes with sacituzumab govitecan in patients with triple-negative breast cancer and central nervous system metastases

Roberta Caputo, Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale", Naples, Italy

PS5-03-16

Clinical Outcomes of ER-Positive to Negative Conversion Versus TNBC: Evidence from an18F-FES PET/CT Guided Propensity-Score-Matched Study

Biyun Wang, Fudan University Shanghai Cancer Center, Shanghai, China

PS5-03-17

Ai-derived Morphometric And Transcriptomic Biomarkers From H&E-stained Images Predict Response To Durvalumab And Olaparib In Metastatic Triple Negative Breast Cancer

Hassan Muhammad, PATHOMIQ, Inc., Cupertino, CA

PS5-03-18

Clinicopathological features and outcomes of triple-negative breast cancer relapsing after pembrolizumab-based neoadjuvant therapy.

Delphine Loirat, Institut Curie – Institute of Women’s Cancers, Paris, France

PS5-03-19

Label-free multimodal multiphoton microscopy reveals spatial lipid alterations associated with inflammation in triple-negative breast cancer following NOS2 suppression and COX-2 inhibition

Wesley Poon, Texas A&M Health Science Center, Bryan, TX

PS5-03-20

Impact of granulocyte-colony stimulating factor use on clinical outcomes in metastatic breast cancer patients receiving chemotherapy

Mara Hofherr, Washington University, St. Louis, MO

PS5-03-21

Rewiring fibroblast function in breast cancer

Prabhat Suman, USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL

PS5-03-22

Lactate driven upregulation of BACH1 promotes metastatic dissemination in triple negative breast cancer

Joselyn Padilla, The George Washington University, Washington, DC

PS5-03-23

Outcomes with first-line treatments for patients with locally advanced or metastatic triple negative breast cancer eligible for anti-PD-(L)1 therapy: A systematic literature review of randomized trials

Xue Wang, Gilead Sciences, Inc, Foster City, CA

PS5-03-24

Thromboxane A2-Prostanoid Receptor (TPR) Blockade with Ifetroban Disrupts Platelet-Tumor Cell Interactions to Reduce Metastasis in Triple-Negative Breast Cancer

Veeresh Toragall, University of Mississippi, Oxford, MS

PS5-03-25

Bexmet trial for metastatix tnbc patients

YING ZHANG, Genome institute of Singapore, A*STAR, singapore, Singapore

PS5-03-26

A Prospective Observational Study of Atezolizumab plus Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer: First Analysis of JBCRG-C08/ATTRIBUTE

Tatsunori Shimoi, National Cancer Center Hospital, Tokyo, Japan

PS5-03-27

Multifaceted Therapeutic Approaches Targeting Oncogenic Pathways to Combat Triple-Negative Breast Cancer

Arisha Arora, Indian Institute of Technology Guwahati, Guwahati, India

PS5-03-28

Reciprocal activation of breast cancer metastases and the lung epithelium during metastatic outgrowth

Jessica L. Christenson, University of Colorado Anschutz Medical Campus, Aurora, CO

PS5-03-29

A retrospectIve observatioNal multicenter study on SacItuzumab Govitecan in mTNBC post NHIA reimbursement in Taiwan (inSiGht)- An interim analysis

Hsu-Huan Chou, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City, Taiwan

PS5-03-30

Neoadjuvant Chemo-Immunotherapy Yields Survival Comparable to Upfront Surgery in Metaplastic Breast Cancer: A National Cancer Database Analysis

Margo Nelis, Cleveland Clinic Foundation, Cleveland, OH

PS5-05-01

Treatment Intensity and Survival in Older Adults with Breast Cancer: Undertreatment or Overtreatment?

Soo-Young Lee, Inha University Hospital, Incheon, Korea, Republic of

PS5-05-03

Survival Outcomes of Chemotherapy Versus Endocrine Therapy in Symptomatic Medullary Infiltration from Metastatic Breast Cancer: A Retrospective Real-World Study

Raelson Rodrigues Miranda, Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil

PS5-05-04

Healthcare resource use among women treated with adjuvant endocrine therapy for hormone-receptor positive breast cancer: associations with induced vasomotor symptoms and treatment adherence

Aswanth Reddy, Mercy, Fort Smith, AR

PS5-05-05

Correlating time to treatment discontinuation with overall survival: real-world data on outcomes for first-line endocrine therapy + CDK4/6 inhibitor in metastatic breast cancer

Erica Mayer, Dana-Farber Cancer Institute, Boston, MA

PS5-05-06

Real-world Clinical Outcomes With Tratuzumab Deruxtecan in Metastatic HER2-low Breast Cancer

Zhonghua Wang, Fudan University Shanghai Cancer Center, Shanghai, China

PS5-05-07

Real-world Patient Characteristics and Treatment Patterns with Pembrolizumab Among Patients with Early-Stage Triple-Negative Breast Cancer in the United States

Amin Haiderali, Merck, North Wales, PA

PS5-05-08

Physician perspectives on treatment decision-making process in high-risk early-stage triple negative breast cancer (esTNBC) in a community oncology setting

Amin Haiderali, Merck, North Wales, PA

PS5-05-09

Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib

Hatem Soliman, Moffitt Cancer Center and Research Institute, Tampa, FL

PS5-05-10

A Comparison of Participant-Reported and Medical Record Stage and Pathology Information in the Susan G. Komen ShareForCuresRegistry

James C Dickerson, Stanford University School of Medicine, Stanford, CA

PS5-05-11

Real-world evaluation of treatment trends in breast cancer: the PRISMA study

Maria Mafalda CPR Nogueira, MSD Portugal, Lisboa, Portugal

PS5-05-12

Real-world outcomes of neoadjuvant therapy for breast cancer: a regional australian cohort study.

Dianheng Bu, Goulburn Valley Health, Shepparton, Australia

PS5-05-13

Pathologic complete response rates after neoadjuvant chemotherapy and pembrolizumab in patients with triple negative breast cancer treated at the Royal Marsden:A retrospective analysis

Chinelo Adaobi Chigbo, University of Nigeria teaching Hospital Ituku Ozalla Enugu and The Royal Marsden Foundation Trust, Enugu and Sutton Surrey, United Kingdom

PS5-05-14

Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

Taha Koray Sahin, Hacettepe University, Ankara, Turkey

PS5-05-15

Sequencing Matters: Impact of EC-first versus Carboplatin-first Ordering on pCR in Triple-Negative Breast Cancer Real-World-Data

Jenny Katharina Wagner, Charité – Universitätsmedizin, Berlin, Germany

PS5-05-16

From Keynote522 to real world evidence: The use of Pembrolizumab in early triple-negative breast cancer

Jonas Roth, University of Regensburg, Regensburg, Germany

PS5-05-17

Real-world effectiveness of Trastuzumab Deruxtecan in HER2-low Metastatic breast cancer: a single-center retrospective study

Yifei Chen, Peking University Cancer Hospital, Beijing, China

PS5-05-18

How Susan G. Komen’s ShareForCures® Research Hub will connect researchers with real-world data shared by breast cancer patients and survivors in the United States.

Kelsi O West, Susan G. Komen, Dallas, TX

PS5-05-19

Real-world comparison of trastuzumab deruxtecan treatment outcomes in HER2-positive or HER2-low metastatic breast cancer patients with and without brain metastases

Vikram Gorantla, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA

PS5-05-20

Real-world treatment patterns and outcomes in patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the US

Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA

PS5-05-22

A Multicenter Retrospective Cohrt Study on Long-Term Outcomes after Partial Mastectomy in Japan.

Goro Kutomi, Juntendo University School of Medicine, Tokyo, Japan

PS5-05-23

Real-world Treatment Patterns of Capivasertib in Metastatic Breast Cancer in the US

Kelsey H Natsuhara, University of California, San Francisco/Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

PS5-05-24

Real-world validation of the 21-gene Recurrence Score in Node Negative Breast Cancer: A Comparative Analysis with TAILORx.

Ryan Rodgerson, University of East Anglia, Norwich, United Kingdom

PS5-05-25

Is the 21-Gene Recurrence Score Validated for Real-World use in Node Positive Breast Cancer? A Retrospective Cohort Study

Ryan Rodgerson, University of East Anglia, Norwich, United Kingdom

PS5-05-26

Analyzing Age-Related Patterns of Second Primary Cancer Sites Following a Primary Breast Cancer Diagnosis

Vontyna Smith, Q-Centrix, Chicago, IL

PS5-05-27

Real-world Clinical Outcomes in Patients with HER2+ Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan After One or More Prior Lines of Therapy: Data from U.S Community Oncology Practices

David Peevyhouse, ONCare Alliance, Tacoma, WA

PS5-05-28

Efficacy of systemic therapy in HER2-low breast cancer with CNS metastases: a “real-world” experience

Bipin Ghimire, Henry Ford Health, Detroit, MI

PS5-05-29

Long-term impact of early-onset breast cancer in brazilian women: a real-world study of years of life lost and clinical outcomes

Diego Lopes Paim Miranda, Einstein Hospital Israelita, São Paulo, Brazil

PS5-05-30

Cycline Dipendent Kinase inhibitors 4/6 and endocrine therapy in the first line of treatment for HR+Her2- advanced breast cancer: a meta-analysis of the published real-world studies

Angela Toss, Azienda Ospedaliero-Universitaria di Modena Policlinico di Modena, Modena, Italy

PS5-04-01

Survival Outcomes in Metastatic Breast Cancer: An analysis of the US population-based SEER database

Alexander Niyazov, Pfizer, New York, NY

PS5-04-02

Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

Christine Brezden-Masley, Mount Sinai Hospital, Toronto, ON, Canada

PS5-04-03

Real world outcomes of use of Capivasertib in patients with HR positive HER2 negative metastatic breast cancer: A single center study

Vinit Singh, Roswell Park Comprehensive Cancer Center, Buffalo, NY

PS5-04-04

Design of a Prospective Registry Study to Evaluate the Decision Impact and Clinical Utility of the Lipidomic-based Blood Test BREASTEST Plus in Breast Cancer Screening

Simon Preston, BCAL Diagnostics, Sydney, Australia

PS5-04-05

Long term Breast Cancer real-world overall survival in France

Olivier Tredan, CENTRE LEON BERARD, LYON, France

PS5-04-06

Current and Emerging Treatment Patterns for Patients with Residual Disease Post-Neoadjuvant Therapy in Early-Stage Triple Receptor-Negative Breast Cancer

Amin Haiderali, Merck, North Wales, PA

PS5-04-07

Real world experience with trastuzumab deruxtecan for metastatic breast cancer at a major Australian cancer centre

Michelle Li, Peter MacCallum Cancer Centre, Melbourne, Australia

PS5-04-10

Comparative analysis of second primary malignancies in invasive lobular versus ductal breast carcinoma: A SEER-based study

Sneha Singh, Sunrise Hospital and Medical Center, Las Vegas, NV

PS5-04-11

Real-world incidence and management of trastuzumab deruxtecan-associated interstitial lung disease

Jasmin Hundal, Cleveland Clinic, Cleveland, OH

PS5-04-12

Inflammatory breast cancer : Monocentric epidemiologic, anatomiclinical features and therapeutic results about 68 patients treated from 2004 to 2024

Hamouda Boussen, Hospital of Ariana, Tunis, Tunisia

PS5-04-13

Intraoperative Radiotherapy in Early-Stage Breast Cancer:Long-Term Survival and Real-World Outcomes from Community Hospitals in Baltimore.

Angel "Luis" OROSCO TTAMINA, MedStar Health Georgetown University (Baltimore) Internal Medicine Program., Baltimore, MD

PS5-04-14

Real-world cardiotoxicity in HER2-positive breast cancer patients in Peru

Jorge Sanchez A, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

PS5-04-15

Improving Adrenal Insufficiency Screening in Patient Receiving Keynote-522

Mara Hofherr, Washington University, St. Louis, MO

PS5-04-16

Analysis of Efficacy, Safety and Cost of Datopotamab Deruxtecan and Sacituzumab Govitecan for Advanced Hormone Positive Breast Cancer Patients

Manaswini Krishnakumar, Saint Vincent hospital, Worcester, MA

PS5-04-17

Male Breast Cancer in Mexico: Experience of a reference breast cancer center in Northeastern Mexico.

Valentina Leitzelar-Bueso, Tecnológico de Monterrey, Monterrey, Mexico

PS5-07-02

NRG-BR008: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO)

Melissa P Mitchell, The University of Texas MD Anderson Cancer Center, Houston, TX

PS5-07-03

Capitrue, capicorn, and capitana: three phase iiib studies to evaluate the use of capivasertib in combination with fulvestrant in patients with advanced breast cancer who have relapsed/progressed on endocrine therapy and cdk4/6 inhibitors reflecting real-world clinical practice in china, germany, belgium, portugal and spain.

Rodrigo Sánchez Bayona*, Hospital Universitario 12 de Octubre, Madrid, Spain

PS5-07-04

NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and recurrence score ≤25 (OFSET)

Sandra Swain, Georgetown Lombardi Comprehensive Cancer Center; Georgetown University Medical Center; and MedStar Health, Washington, DC

PS5-07-05

A prospective multicenter study on the clinical utility of virtual sonography for metastatic axillary lymph nodes during neoadjuvant chemotherapy in breast cancer patients (FUSION-03)

Manabu Futamura, Gifu University Hospital, Gifu, Japan

PS5-07-06

BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors

Andreas Varkaris, Massachusetts General Hospital, Boston, MA

PS5-07-07

Toward optimization of treatment strategies for early breast cancer: a multicenter observational study integrating whole genome and transcriptome sequencing within the National Whole Genome Project in Japan (WJOG16822B)

Jun Masuda, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

PS5-07-08

CDK4/6 inhibitor (CDK4/6i) dosing knowledge (CDK) study: A pragmatic randomized trial of indicated vs. titrated CDK4/6i dosing in older adults with HR+/HER2- metastatic breast cancer (MBC)

Erica L Mayer, Dana-Farber Cancer Institute, Boston, MA

PS5-07-09

A randomized clinical trial comparing ctDNA-directed therapy change with standard of care in patients with metastatic triple negative breast cancer (mTNBC)

Jessica Mezzanotte Sharpe, Vanderbilt University Medical Center, Nashville, TN

PS5-07-10

Young HOPE/JCOG2402: A Randomized Phase III Study of Response-Guided Therapy Following Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer

Makiko Ono, The Cancer Institue Hospital of JFCR, Tokyo, Japan

PS5-07-11

A phase 1 study of LY4257496, a novel GRPR-targeted radioligand therapy, in patients with GRPR-positive metastatic ER+ breast cancer and other advanced solid tumors – OMNIRAY (Trial in Progress)

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY

PS5-07-12

Opt-pembro: a phase III randomized trial of adjuvant pembrolizumab omission in patients with early-stage triple-negative breast cancer achieving pathologic complete response after neoadjuvant chemo-immunotherapy

Joana Mourato Ribeiro, Institute Gustave Roussy, Paris, France

PS5-07-13

Impact of pegulicianine on radiotherapy decisions and long-term outcomes in patients undergoing breast conserving surgery

Jorge Ferrer, Lumicell, Inc., Newton, MA

PS5-07-14

The CROWN Study (CaRdiac Outcomes With Near-complete estrogen deprivation)

Sarah Hatcher, Duke University, Durham, NC

PS5-07-15

A randomized phase II study to evaluate the efficacy and safety of Trastuzumab deruxtecan (T-DXd) versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of hormone receptor-positive (HR+) and HER2-low/ultralow advanced breast cancer (ABC) patients classified as non-luminal subtype according to gene expression profiling: the PONTIAC study

Javier Cortes, IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana, Madrid, Spain

PS5-07-16

Cappa, a phase 2 study to evaluate capecitabine plus pembrolizumab as post-operative adjuvant therapy for triple-negative breast cancer with residual disease after neoadjuvant chemo-immunotherapy

Delphine Loirat, Institut Curie – Institute of Women’s Cancers, Paris, France

PS5-07-17

A prospective, direct-to-patient study to evaluate clinical and molecular mechanisms of resistance to capivasertib in estrogen receptor-positive metastatic breast cancer

Jacqueline Jialin Tao, Columbia University Irving Medical Center, New York, NY

PS5-07-18

Advancing personalized treatment of patients with metastatic breast cancer by functional drug screening and IMC profiling

Marcus Vetter, Cantonal Hospital Baselland, Liestal, Switzerland

PS5-07-19

Ecog-acrin tomosynthesis mammographic imaging screening trial (tmist) – update for 2025

Etta Pisano, American College of Radiology, Philadelphia, PA

PS5-07-20

Trial in progress: Phase 1 Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer (NCI Protocol #10546)

Roberto Leon-Ferre, Mayo Clinic, Rochester, MN

PS5-07-21

Tropion-breast06: multicenter, multinational, open-label, single-arm, phase 3b study of datopotamab deruxtecan (dato-dxd) in patients (pts) with locally advanced inoperable or metastatic hr+/her2 ihc 0 breast cancer (bc) refractory to endocrine therapy

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY

PS5-07-22

Herthena-breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) unresectable locally advanced or metastatic breast cancer

Barbara Pistilli, Gustave Roussy, Villejuif, France, and IHU PRISM National PRecISion Medecine Center in Oncology, Gustave Roussy, Villejuif Cedex, France

PS5-07-23

Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase 2 Study of Tetrathiomolybdate (TM), an oral copper depletion agent plus capecitabine +/- pembrolizumab in patients with breast cancer at high risk of recurrence (NCT06134375).

Linda Vahdat, Dartmouth-Hitchcock, Lebanon, NH

PS5-07-24

A randomized phase III trial for evaluating the efficacy of adjuvant abemaciclib in patients with locoregional recurrence of hormone receptor-positive, HER2-negative breast cancer: JCOG2313 (AURA study)

Emi Tokuda, Fukushima Medical University, Fukushima, Japan

PS5-07-25

Phase I Study of TAS0728 in Patients with Advanced Solid Tumors with HER2 Aberration (TAIBRAKHER Study)

Kazuki Nozawa, Nagoya City University, Nagoya, Japan

PS5-07-26

Ribociclib with fulvestrant versus physician’s choice treatments in patients who recurred after completion of adjuvant cyclin-dependent kinase 4/6 inhibitors as first-line treatment in HR+, HER2- advanced breast cancer

Hee Kyung Ahn, Samsung Medical Center, Seoul, Korea, Republic of

PS5-07-27

INAVO123: Phase 3 study of first-line inavolisib / placebo + a cyclin-dependent kinase 4/6 inhibitor + letrozole in participants with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-sensitive advanced breast cancer

Reva K. Basho, Ellison Medical Institute, Los Angeles, CA

PS5-07-28

The SURVIVE HERoes study NCT06643585: Targeting molecular relapse in breast cancer.

Kerstin Pfister, University Hospital Ulm, Ulm, Germany

PS5-07-29

Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients with previously treated HR+/HER2− metastatic breast cancer

Geoffrey J. Lindeman, Peter MacCallum Cancer Centre and the Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

PS5-07-30

Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation

Matthew P Goetz, Mayo Clinic, Rochester, MN

PS5-08-01

Hormone receptor (HR)-positive HER2 negative breast cancer patients treated with preoperative Elacestrant and PULSAR adaptive radiotherapy: a phase II study (HELP Trial)

Luca Visani, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

PS5-08-02

Vacuum Assisted Excision (VAE): A single-step approach to the diagnosis and percutaneous treatment of Early Breast Cancer (THE VAE BReast 01 TRIAL)

Henrique Lima Couto, Redimama-Redimasto, Belo Horizonte, Brazil

PS5-08-03

Denali-1: a seamless phase 1/2 study of A2B395, a logic‑gated, allogeneic, Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with triple-negative breast cancer and other EGFR-expressing solid tumors with HLA-A*02 loss of heterozygosity (LOH)

Jennifer Marie Specht, University of Washington/Fred Hutch Cancer Center, Seattle, WA

PS5-08-04

A phase 1b, multi-centre, open-label, randomized study to evaluate the safety, tolerability, and clinical activity of combining paxalisib with olaparib or pembrolizumab/chemotherapy in patients with advanced breast cancer

Michelle Nottage, The Royal Brisbane and Women's Hospital, Herston, Australia

PS5-08-05

Predictive Role of the Gut Microbiome in Abemaciclib-Associated Diarrhea: A Prospective Translational Pilot Study

Soo Jung Lee, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of

PS5-08-06

A prospective, multicenter comparative pilot study to evaluate targeting axillary lymph node surgery for patients with clinically node-positive breast cancer (LUCAS study, KBCSG36)

Joon Suk Moon, Kyungpook National University, Daegu, Korea, Republic of

PS5-08-07

Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer – HER2 PARADIGM trial

Adriana Kahn, Yale University, New Heaven, CT

PS5-08-08

A phase II neoadjuvant clinical trial of the androgen receptor inhibitor darolutamide in early-stage androgen receptor positive (AR+) triple-negative breast cancer (NCT 07016399)

Lila Duke, Vanderbilt University Medical Center, Nashville, TN

PS5-08-09

A Pilot, Single-Arm, Phase II Trial of Tamoxifen plus Pegylated Liposomal Doxorubicin in Patients with Metastatic Triple Negative Breast Cancer

Zunairah Shah, Roswell Park Cancer Center, Buffalo, NY

PS5-08-10

Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Snehal Patel, Greenwich LifeSciences, Stafford, TX

PS5-08-11

Trial in Progress: Phase II Open-Label Study of ARX788 (anti-HER2 Antibody Drug Conjugate (ADC)) for Patients with HER2-Low Locally Advanced Unresectable or Metastatic Breast Cancer

Laura A Huppert, University of California, San Francisco, San Francisco, CA

PS5-08-12

Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387)

Nina Ditsch, University Augsburg, Augsburg, Germany

PS5-08-13

Reevaluating Follow-Up in Early Breast Cancer, guided by Liquid Biopsy: the SURVIVE Study (NCT05658172)

Kerstin Pfister, University Hospital Ulm, Ulm, Germany

PS5-08-14

Destiny-breast respond her2-low europe: description of first enrolled patients in the non-interventional study of t-dxd in her2-low metastatic breast cancer

Valentina Guarneri, Veneto Institute of Oncology (IOV); Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

PS5-08-15

Targeted axillary dissection vs axillary node clearance in patients with positive axillary nodes in early breast cancer: a multicentre, pragmatic, phase 3 randomised controlled trial

Shelley Potter, Bristol Medical School, Bristol, United Kingdom

PS5-08-16

Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Controlled Trial

Ursina Zürrer, Cantonal Hospital Winterthur, Winterthur, Switzerland

PS5-08-17

Melody: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (Eubreast-4 / iBra-net, Nct 05559411)

Maggie Banys-Paluchowski, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

PS5-08-18

Trofuse-011: a phase 3, randomized, open-label study of sacituzumab tirumotecan with or without pembrolizumab vs treatment of physician’s choice for previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer

Aditya Bardia, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA

PS5-08-19

Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy

Kevin M. Kalinsky, Emory University, Atlanta, GA

PS5-08-20

A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007

Julia R White, University of Kansas Medical Center Comprehensive Cancer Center, Kansas City, KS

PS5-08-21

Prospective breast cancer clinical validation study of an ultrasensitive, tumor-informed, whole genome, circulating tumor DNA assay to detect molecular residual disease and predict recurrence of high-risk early breast cancer treated with standard (neo)adjuvant therapy; NSABP B-64/EXActDNA/003/NCT06401421.

Mark Basik, Jewish General Hospital, Montréal, QC, Canada

PS5-08-22

Patients with breast cancer and axillary involvement undergoing Sentinel LYMph Node Biopsy versus Targeted AXillary Dissection after primary systemic treatment: which axillary staging saves more lymphnodes? A registry-based randomized controlled trial (SLYMT-AXSANA EUBREAST 3R)

Maria Luisa Gasparri, Ente Ospedaliero Cantonale, Lugano, Switzerland

PS5-08-24

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-related Quality of Life: A Feasibility Trial for Women with HR+/HER2- Early Breast Cancer

Sailaja Kamaraju, Medical College of Wisconsin, Milwaukee, WI

PS5-08-25

ReDiscover-2, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)

Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

PS5-08-26

The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ

Anna Daily, PreludeDx, Laguna Hills, CA

PS5-08-27

Single arm phase II study with abemaciclib and bicalutamide in locoregionally advanced inoperable or metastatic androgen receptor-positive triple-negative breast cancer (ABBICAR)

Kristien Borremans, KU Leuven, Leuven, Belgium

PS5-08-28

Phase I pilot of pegylated liposomal doxorubicin, CD40 agonist antibody CDX-1140, and Flt3 ligand CDX-301 in advanced HER2-negative breast cancer

Sangeetha M Reddy, University of Texas Southwestern Medical Center, Dallas, TX

PS5-08-29

Trend-02 study – a phase ii exploratory de-escalation trial of neoadjuvant sacituzumab govitecan plus tislelizumab (sg/i) in early triple-negative breast cancer

Qiang Zhang, Cancer Hospital of DaLian University of Techology，Liaoning Cancer Hospital & Institute, Shenyang City, Liaoning Province, China

PS5-08-30

Cryoablation versus Breast Surgery in the Local Treatment of Early-Stage Breast Cancer: Protocol for the CRYSTAL-SIX Trial (CRYoablation for Small Tumors As Local Treatment)

Vanessa Monteiro Sanvido, Hcor, São Paulo, Brazil

PS5-09-01

The TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65) Trial

Erica Schleicher, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA

PS5-09-02

Phase 2 study of adjuvant liposomal doxorubicin and carboplatin for early-stage triple negative breast cancer

Mridula George, Rutgers Cancer Institute, New Brunswick, NJ

PS5-09-03

Prospective longitudinal study of circulating serum progranulin (PGRN/GP88) levels and its association with tumor response to therapies in patients with metastatic breast cancer (MBC)

Katherine H R Tkaczuk, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD

PS5-09-04

Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769)

Rita Nanda, The University of Chicago, Chicago, IL

PS5-09-06

A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient’s Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy – SELECT Trial

Jing Du, Yale Cancer Center, New Haven, CT

PS5-09-07

Etic-lm : a multicenter, single-arm, phase 2 study evaluating the efficacy of oral tucatinib, oral capecitabine, and intrathecal trastuzumab in patients with her2-positive metastatic breast cancer with leptomeningeal metastases, a ucbg study

Thomas Bachelot, Centre Léon Bérard, LYON, France

PS5-09-08

Despatil study: a phase II trial of de-escalated neoadjuvant chemotherapy for early-stage triple-negative breast cancer guided by tumor-infiltrating lymphocytes (TILs) and radiologic response

Renata C Bonadio, Instituto D'Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil

PS5-09-09

Ctc-express: a prospective observational study for ctc biomarker expression and cfdna/cfrna assessment in metastatic breast cancer

Marija Balic, UPMC, Pittsburgh, PA

PS5-09-10

A randomized phase II study comparing monthly versus 3-monthly GnRH agonist for ovarian function suppression in premenopausal patients with HR-positive breast cancer: study design and rationale

Daniella Audi Blotta, Memorial Sloan Kettering Cancer Center, New York, NY

PS5-09-11

Dose-dense Paclitaxel with Empegfilgrastim vs weekly Paclitaxel in luminal B HER2-negative early breast cancer (PULSE trial)

Petr Krivorotko, NMRC of Oncology named after N.N. Petrov, Saint Petersburg, Russian Federation

PS5-09-12

Small: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer – a UK phase III randomised multi-centre trial

Stuart McIntosh, Queen's University Belfast, Belfast, United Kingdom

PS5-09-13

Evaluation of the diagnostic accuracy of ultra-fast ConfocAl imaging for rEtroareolar Limit in nIpple-sparing mAstectomy: Camelia project

Angelica Conversano, GUSTAVE ROUSSY, Villejuif, France

PS5-09-14

Rossini-platform: a ‘basket factorial multi arm multi stage (mams)’ platform trial in surgical site infection – the breast surgery pillar

Katherine Fairhurst, University of Bristol, Bristol, United Kingdom

PS5-09-15

ERADICATE: A phase Ib/II study of elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer

Sarah L. Sammons, Dana Farber Cancer Institute, Boston, MA

PS5-09-16

A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+/HER2- MBC (START-002 trial)

Steven J Isakoff, Mass General Cancer Center, Boston, MA

PS5-09-17

Phase 1 results of a Phase I II study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Coy Heldermon, University of Florida, Gainesville, FL

PS5-09-19

Flex: from genomic profiling to real-world insights in 30,000 patients with early-stage breast cancer

Linsey P Gold, Comprehensive Breast Care, Troy, MI

PS5-09-20

A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01)

Peter Schmid, Queen Mary University of London, London, United Kingdom

PS5-09-21

Feasibility of Clinical Nurse-Initiated Geriatric Assessments in Breast Medical Oncology Clinic: A Pilot Program

Rima Patel, Icahn School of Medicine at Mount Sinai, New York, NY

PS5-09-22

Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer

Senthil Damodaran, MD Anderson Cancer Center, Houston, TX

PS5-09-23

A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)

Peter A Kaufman, University of Vermont Cancer Center, Burlington, VT

PS5-09-25

Claire: a multicenter, prospective single-arm phase II study, evaluating liquid biopsy guided intensified follow-up surveillance in patients with intermediate to high-risk ER+/HER2-negative early-stage breast cancer

Mitchell J Elliott, Princess Margaret Cancer Centre, Toronto, ON, Canada

PS5-09-26

Digital health adherence companion study for tetrathiomolybdate (TM) plus capecitabine in triple-negative breast cancer

Arvind Suresh, University of California San Francisco, San Francisco, CA

PS5-09-27

A phase i/ii single-arm trial of azenosertib (zn-c3) combined with carboplatin and pembrolizumab in patients with metastatic triple-negative breast cancer (zap-it)

Filipa Lynce, Dana-Farber Cancer Institute, Boston, MA

PS5-09-28

Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER-positive/HER2-negative Early-stage Breast Cancer

Mitchell J Elliott, Princess Margaret Cancer Centre, Toronto, ON, Canada

PS5-09-29

Radiant study: Phase 1b study of pre-op radiation with abemaciclib and letrozole in early-stage hormone-receptor positive breast cancer

Mridula George, Rutgers Cancer Institute, New Brunswick, NJ

PS5-09-30

A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER+/HER2− locally advanced or metastatic breast cancer

Fengting Yan, Swedish Cancer Institute, First Hill-True Family Women's Cancer Center, Seattle, WA

PS5-12-16

A Phase 2 Trial of (Z)-endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+, HER2-, Breast Cancer (EVANGELINE)

Matthew P Goetz, Mayo Clinic, Rochester, MN

PS5-12-17

A phase 1/2 study of AVZO-023, a next-generation selective cyclin-dependent kinase 4 inhibitor (CDK4i), as a single agent and in combination with AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), and/or endocrine therapy in patients with advanced solid tumors

Timothy A Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

PS5-12-18

OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer

Sara M Tolaney, Dana Farber Cancer Institute, Boston, MA

PS5-12-19

Pre-ispy trial: a phase i/ib oncology platform program (pre-i-spy-p1) nct05868226

PAULA R POHLMANN, University of Texas MD Anderson Cancer Center, Houston, TX

PS5-12-20

Synthesis-breast: a prospective early-phase trial of a synthetic lethality-focused algorithm to identify therapeutic options in metastatic breast cancer

Aanika B Warner, National Institutes of Health, Bethesda, MD

PS5-12-21

Herthena-breast03: a phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan (HER3-DXd) + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer

Joyce O'Shaughnessy, Baylor University Medical Center, Texas Oncology, US Oncology and Sarah Cannon Research Institute, Dallas, TX

PS5-12-22

Trofuse-012: a phase 3, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician’s choice in participants with triple-negative breast cancer who received neoadjuvant therapy and did not achieve a pathological complete response at surgery

Heather L McArthur, UT Southwestern Medical Center, Dallas, TX

PS5-12-23

Herthena-breast01: a phase 1b/2, multicenter, open-label, dose-finding study to evaluate the safety and antitumor activity of patritumab deruxtecan (HER3-DXd) in HER2+ unresectable locally advanced or metastatic breast cancer

Sara Tolaney, Dana-Farber Cancer Institute and Harvard Medical School Boston, Boston, MA

PS5-12-25

Trofuse-032: a phase 3, randomized study of pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer or hormone receptor-low-positive (HR-low+)/ human epidermal growth factor receptor 2-negative (HER2−) breast cancer

Nadia Harbeck, LMU University Hospital, Munich, Germany

PS5-10-01

Misinformation about breast cancer treatment on social media: Implications for engagement with patients and social media

Margaret Gatti-Mays, The Ohio State University Comprehensive Cancer Center, Columbus, OH

PS5-10-02

Evaluating the impact of educational materials about biomarker testingfor patients with metastatic breast cancer

Theresa Petee, Living Beyond Breast Cancer, Bala Cynwyd, PA

PS5-10-03

The Influence of Sociodemographic Factors on Barriers to Breast Cancer Screening

Alice Barros Câmara, University of São Paulo, São Paulo, Brazil

PS5-10-04

Willingness to participate in a trial comparing standard genetic counseling versus genetic counseling with personalized cancer risk estimates in patients with Li-Fraumeni syndrome

Ashley H Woodson, MD Anderson Cancer Center, Houston, TX

PS5-10-05

Implementation of strategies across sectors to reduce breast cancer in Greater Houston

Rosalind S Bello, The University of Texas MD Anderson Cancer Center, Houston, TX

PS5-10-06

Evaluating the Increasing Proportion of Breast Cancer among Patients Aged 21 to 30 Since Year 2016

Brianna Cattelino, Drexel University College of Medicine, Philadelphia, PA

PS5-10-08

Advance-bc: a prospective single-center registry to capture real-world outcomes in advanced breast cancer

Abbey J Kaler, The University of Texas MD Anderson Cancer Center, Houston, TX

PS5-10-09

Prognostic factor pregnancy associated breast cancer by assisted technical reproduction

Maxim Izquierdo, Hospital Universitario Dexeus, Barcelona, Spain

PS5-10-10

“You have to work with me”: a thematic analysis of patient experiences in breast cancer treatment decision-making

Molly E Boll, University of Chicago, Chicago, IL

PS5-10-11

Metachrone contralateral breast cancers: Differences in detection mode, Nottingham Prognostic Index, ER, PR and HER2

Elien Bloemen, KU Leuven, Leuven, Belgium

PS5-10-13

Exploring the Role of Social Media in Shaping Breast Cancer Treatment Decisions Among Women

Tiare Africa Piñeiro, IAF, Buenos Aires, Argentina

PS5-10-14

How Reliable is YouTube Content Targeting Arabic-Speaking Breast Cancer Patients Regarding Post-Mastectomy Reconstruction?

Marya Alsuhaibani, McGill University, Montreal, QC, Canada

PS5-10-15

Comparing User Experience Between AI-powered Thermal Test and Mammography: Results from a Single Center Study

Pavani Chalasani, George Washington Cancer Center, Washington, DC

PS5-10-16

Physical Therapy and Oncology Rehabilitation Referral and Enrollment Patterns among Breast Cancer Patients

Mary Imboden, Providence St Vincent Medical Center, Portland, OR

PS5-10-17

Barriers to Breast Cancer Screening from the Perspective of Primary Care Professionals

Alice Barros Câmara, University of São Paulo, São Paulo, Brazil

PS5-10-18

Trial in Progress: The Physical Activity Index (PAI) Feasibility Pilot Trial for Breast and Colon Cancer Survivors in North Carolina

Shirley Bluethmann, Wake Forest University School of Medicine, Winston-Salem, NC

PS5-10-19

Breast cancer in young women at a private center in Chile

Maria Trinidad Esperanza Gonzalez, Clinica Alemana de Santiago, Santiago, Chile

PS5-10-20

Invasive lobular breast cancer and surveillance: A patient experience survey study.

Mason Mitchell-Daniels, Lobular Breast Cancer Alliance Inc., White Horse Beach, MA

PS5-10-21

Real-world patterns and preferences in the use of diagnostic imaging for breast cancer staging in Hispano-America: A multinational physician survey

William Armando Mantilla, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center, Bogota, Colombia

PS5-10-22

Allostatic Load and Risk of Obesity Related and Total Cancer in Postmenopausal Women

Jie Chi, Memorial Sloan Kettering Cancer Center, New York, NY

PS5-10-23

Assessing Clinical and Sociodemographic Trends in Contralateral Prophylactic Mastectomy at an Urban Tertiary Care Center

Ariella Deborah Simoni, Montefiore Einstein, Bronx, NY

PS5-10-24

Cardiac Monitoring in Patients Receiving HER2-Directed Therapy: A Meta-Analysis and Cost-Effectiveness Analysis

Ilana Schlam*, Dana Farber Cancer institute, Boston, MA

PS5-10-25

Comparison of survival and recurrence outcomes among breast cancer patients: breast-conserving surgery versus medically necessary and patient preference mastectomy

Claire Liu, University of British Columbia, Vancouver, BC, Canada

PS5-10-27

Integrating Virtual Collaborative Care Behavioral Health in Breast Cancer Care: Improving Outcomes in Mental Health, Adherence, and Racial Equity

Nina Balanchivadze, Virginia Oncology Associates, Norfolk, VA

PS5-10-28

A Survivor-Led Patient Navigation Model to Improve Breast Cancer Treatment Adherence in India: Results from a Pilot Project

Soumen Das, Institute of Breast Disease, NCRI Hospital, Kolkata, Kolkata, India

PS5-10-29

Factors Associated with Discussion of Contralateral Prophylactic Mastectomy (CPM) During Surgical Consultations

Heather Neuman, University of Wisconsin, Madison, WI

PS5-10-30

A randomized survey study of structured reflective questions and willingness to participate in window of opportunity trials

Colin Bergstrom, Stanford, Stanford, CA

PS5-11-01

Cost-effectiveness analysis of next-generation sequencing (ngs) panel including brca1 and brca2 genes for women diagnosed with non-metastatic breast cancer in brazil

Henrique Lima Couto, Redimama-Redimasto, Belo Horizonte, Brazil

PS5-11-02

Exploring Sociodemographic and Structural Barriers to Timely Surgery in ER+ HER2- Breast Cancer: A Single-Institution Study in the Bronx

Susan Laura Jao, Montefiore Medical Center, Bronx, NY

PS5-11-03

The value of innovation in breast cancer treatment: Real Option Value of Olaparib for First-Line Treatment of gBRCA1,2 Pathogenic Mutation HR+/HER2-negative and Triple Negative Metastatic Breast Cancer

Cynthia L Gong, Curta Inc., Seattle, WA

PS5-11-04

Patient Out-of-Pocket Exposure from Initial Staging Breast MRI: Quantifying Financial Toxicity in Breast Cancer Care

Tomas Dvorak, Orlando Health, Orlando, FL

PS5-11-05

Multidisciplinary Team Decision-Making in Breast Cancer: Real-World Insights from the PRISMA Study

Maria Mafalda CPR Nogueira, MSD Portugal, Lisboa, Portugal

PS5-11-06

Regional disparities and temporal trends in breast cancer staging and time to treatment in Brazil: A 20-Year analysis of the hospital-based cancer registry

Anne Dominique Nascimento Lima, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

PS5-11-07

The Global Landscape of Practice-Changing Breast Cancer De-Escalation Randomized Trials

Lina M. Adwer, University of Nebraska Medical Center, Omaha, NE

PS5-11-08

Characterization and survival outcomes of young women with breast cancer in Mexico: 5-year results of the Joven & Fuerte prospective cohort

Fernanda Mesa-Chavez, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico

PS5-11-09

Increasing rates of germline genetic testing in Veterans with breast cancer

Akiko Chiba, Durham VA Medical Center, Durham, NC

PS5-11-10

Implementing an Our Practice Advisory (OPA) to provide clinical decision support for adjuvant CDK4/6 inhibitors in early-stage hormone receptor positive breast cancer: The Mayo Clinic Experience

Sarah Premji, Mayo Clinic, Rochester, MN

PS5-11-11

A common sense oncology values-to-action framework for patient-centered randomized trials in oncology

Michelle Tregear, National Breast Cancer Coalition, Washington, DC

PS5-11-13

Patient navigation improves treatment compliance in women with breast cancer: A prospective observational audit from India

Nishu S Goel, Tata Memorial Center, Mumbai, India

PS5-11-15

The intersection of social determinants of health and healthcare needs among breast cancer patients: A qualitative content analysis

Anjanette Alise Wells, University of Cincinnati, Cincinnati, OH

PS5-11-16

Impact of GLP-1 Receptor Agonist Exposure on the Long-Term Survival in Breast Cancer Patients

Joanne Mortimer, City of Hope, Duarte, CA

PS5-11-17

An integrative approach to improving outcomes for inflammatory breast cancer (IBC) patients: creating a diagnostic tool, advocating for ICD-10-CM codes, and establishing a task force to address critical research gaps

Lindsey J. Anstine, Susan G. Komen, Dallas, TX

PS5-11-18

Racial and Ethnic Representation in Antibody-Drug Conjugate Clinical Trials for Breast Cancer: A 10-Year Review

Zouina Sarfraz, Miami Cancer Institute, Baptist Health South Florida, Miami, FL

PS5-11-19

Insurance Type Predicts Time-to-Approval for Proton Therapy in Breast Cancer

Aren S Saini, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

PS5-11-20

Long Term Impact of Medicaid Expansion on Breast Cancer Mortality

Ishani Dwivedy, Providence Day School, Charlotte, NC

PS5-11-21

Evaluation of patient experience from participation in a randomised trial

Phoebe Mila Coco Collins, University of Cambridge, Cambridge, United Kingdom

PS5-11-22

Disparities in Mammography Screening in a Welfare-State Healthcare System: Data from 100,000 Women in Israel

Hadas Kadar Sfarad, Kaplan Medical Center, Rehovot, Israel

PS5-11-23

Timing of Oncotype DX Testing and Its Impact on Treatment Initiation in ER+/HER2-/N0 Breast Cancer Patients

Eleni Kohilakis, Montefiore Medical Center, Bronx, NY

PS5-11-24

Does Early Awareness of Clinical Trials Translate to Increased Adoption of Results? Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Trial

Ko Un Park, Dana-Faber Cancer Institute/Brigham and Women's Hospital, Boston, MA

PS5-11-25

Oncology patient engagement to improve outcomes: the power of patient navigation

SANDRA MARQUES SILVA GIOIA, PinkMapp, Rio de Janeiro, Brazil

PS5-11-27

Impact of Protein Energy Malnutrition on Clinical Outcomes in Hospitalized Breast Cancer Patients

Kalaivani Babu, Allegheny General Hospital, Pittsburgh, PA

PS5-11-29

Implementation of a Rapid Access Referral Program for Breast Cancer: A Quality Improvement Project

Devin Johnson, University of North Carolina, Chapel Hill, NC

PS5-11-30

Racial and ethnic differences in site of metastasis at presentation and treatment in de novo metastatic triple-negative breast cancer

Jincong Q. Freeman, UChicago Medicine Comprehensive Cancer Center, Chicago, IL

PS5-12-01

Breast cancer in chile: incidence rising, young women dying, why?

Claudio Salas, Clinica Alemana de Santiago, Santiago, Chile

PS5-12-02

Quantifying the value of progression-free survival in breast cancer treatment among a general population of US women

Jaehong Kim, FTI Consulting, Los Angeles, CA

PS5-12-03

Improving Clinical Trial Awareness Through Community Education: A Retrospective Survey of Diverse South Florida Participants

Ana Sandoval-Leon, Miami Cancer Institute, Miami, FL

PS5-12-04

Initial factors affecting recruitment of Black women in the U.S. Mid-South region diagnosed with or at elevated risk for de novo metastatic breast cancer

Janeane N. Anderson, University of Tennessee Health Science Center, Memphis, TN

PS5-12-06

Supporting language access for persons with a breast cancer diagnosis

Ana María López, Thomas Jefferson University, Philadelphia, PA

PS5-12-07

Breast Cancer Treatment in Brazil: The Gap Between Incorporation and Real-World Access

Luciana Holtz de Camargo Barros, Oncoguia Institute, São Paulo, Brazil

PS5-12-08

Survival Outcomes and Tumor Site Distribution by Molecular Subtype in Breast Cancer Patients Under 40

Muhammad Noorani, University of Texas Rio Grande Valley School of Medicine, McAllen, TX

PS5-12-09

Breast cancer patient attitudes and experiences of health care in the post-COVID era: Landscape of recovery and trust at an urban US cancer center

Alyson Moadel-Robblee, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY

PS5-12-10

Impact of KEYNOTE-522 on BneoCT: An Institutional Quality Measure Improvement Analysis

Karishma Vijay Rupani, Icahn School of Medicine at Mount Sinai, New York, NY

PS5-12-11

Clinicopathological Characteristics and Treatment Patterns in Young Women with Breast Cancer at the Brazilian National Cancer Institute

Matheus Feres de Melo, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

PS5-06-01

Tattoo Ink Fluorescence Interfering with Axillary Reverse Mapping Using Indocyanine Green in Breast Conservation Surgery

Aishwarya Vijay, Marshall University Joan C. Edwards School of Medicine, Huntington, WV

PS5-06-02

Cdk4/6 inhibitor-induced interstitial lung disease: a rare but severe complication in breast cancer treatment

Stephanie Adel Haddad, UT Health San Antonio/Mays Cancer Center, San Antonio, TX

PS5-06-03

Early-stage hormone receptor-positive metaplastic breast cancer treated with chemo-immunotherapy: a case report

Dali Edwards, Medical University of South Carolina, Charleston, SC

PS5-06-04

Cdk4/6 inhibitor in extensive cutaneous metastasis breast carcinoma: a case report

Ricardo Fernández-Ferreira, HOSPITAL CENTRAL SUR DE ALTA ESPECIALIDAD PEMEX, CIUDAD DE MEXICO, Mexico

PS5-06-05

A Rare Case of Breast Cancer Recurrence Presenting as Laryngeal Metastasis

Divya Samat, Tower Health-Reading Hospital, Reading, PA

PS5-06-06

Case Series on Early Methotrexate Use in Reducing Morbidity in Granulomatous Mastitis

Agnes M Otieno, Howard University, Washington, DC

PS5-06-07

A case report of veno-occlusive disease (VOD) in a patient with metastatic triple-negative breast cancer receiving trastuzumab deruxtecan.

Kenna Noel Koehler, The Ohio State University James Comprehensive Cancer Center, Columbus, OH

PS5-06-08

Pseudocirrhosis Following Great Response to CDK4/6 Inhibitor and Endocrine Therapy in a Premenopausal Patient With HR+/HER2- Metastatic Breast Cancer

Bruna Migliavacca Zucchetti, Hospital 9 de Julho – Américas Oncologia, São Paulo, Brazil

PS5-06-09

Immunotherapy induced Kikuchi Fujimoto (Histiocytic Necrotizing Lymphadenitis): A Rare Immune Related Adverse Event

Briana To, The Ohio State University Comprehensive Cancer Center, Columbus, OH

PS5-06-10

A Rare Metastasis of Renal Cell Carcinoma to the Breast: A Case Report

Madelyn G Moulton, Rosalind Franklin University, North Chicago, IL

PS5-06-11

Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in A Diverse Cohort

Keerthana Sureshkumar, University of Miami, Miami, FL

PS5-06-12

Atypical Presentation of Invasive Lobular Carcinoma Presenting as Periorbital Swelling Despite Negative Mammogram

Sarah A Shaker, UT Health Houston, Houston, TX

PS5-06-13

Carcinoma en Cuirasse

Karishma Vijay Rupani, Icahn School of Medicine at Mount Sinai, New York, NY

PS5-06-14

Unexpected B-hCG elevation in metastatic inflammatory breast cancer: A diagnostic dilemma

Katherine Klein, MD Anderson Cancer Center, Houston, TX

PS5-06-15

Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous transformation involving the male breast: A rare case report and comprehensive review of clinicopathologic features

Anne Dominique Nascimento Lima, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

PS5-06-16

A case of triple negative breast cancer in Lynch Syndrome

Harshil Bhatt, Maine Health Cancer Care, South Portland, ME

PS5-06-18

Paraneoplastic Encephalitis in Breast Cancer

Chinyere Onyeukwu, Rush University, chicago, IL

PS5-06-19

Sacituzumab Govitecan Combined with Anti-angiogenic Therapy and Radiotherapy in a BRCA1-Mutated Triple-Negative Breast Cancer Patient with Multiple Recurrences: A Case Report

Chunfang Hao, Tianjin Cancer Hospital Airport Hospital, Tianjin, China

PS5-06-20

Autoimmune Hemolytic Anemia Triggered by Neoadjuvant Pembrolizumab in Triple Negative Breast Cancer: A Case Report

Angela Rita Slaybe, Baptist Health Miami Cancer Institute, Miami, FL

PS5-06-21

When Signet Ring Cells Mislead: A Case of Metastatic Breast Cancer Presenting as Gastric Malignancy

Jared Eckman, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

PS5-06-22

Atypical recurrence of invasive lobular breast carcinoma with hormone receptor loss: a Case Report

Rita Quaresma Ferreira, Local Health Unit of São José, Lisbon, Portugal

PS5-06-23

A Functional Reversal of Leptomeningeal Disease without CNS Directed Therapy

Emily Sargent, UTHealth Houston, Houston, TX

PS5-06-24

When Therapy Leaves a Mark: A Case of Ribociclib-Induced Vitiligo Reversed with Abemaciclib

Daniela Urueta Portillo, UT health Mays Cancer Center, San Antonio, TX

PS5-06-26

Androgen Receptor Positive Breast Cancer in a Female-to-Male Transgender Individual

Kendra Wilson, UT Health Science Center Tyler, Tyler, TX

PS5-06-27

Reframing Breast Cancer Therapies in a Rare Context – A Case of Metastatic Mammary-Like Vulvar Carcinoma Treated with Breast Cancer Regimens

Dali Edwards, Medical University of South Carolina, Charleston, SC

PS5-06-28

Carcinoma en Cuirasse and Radiation-Induced Morphea

Holly Grace, UT Southwestern Medical Center, Dallas, TX

PS5-06-29

Phantom limb pain patients with Breast cancer: Updates in rehabilitation paradigms

Breanne Nguyen, UT Health San Antonio, San antonio, TX

PS5-04-30

A Rare Case of Fibroadenoma After Long-Term Estrogen Therapy in a Transgender Woman

Joseph Sahagun, University of Illinois, Chicago, IL

PS5-10-26

Breast Cancer Screening Patient Navigation Decreases Time to Screening and Diagnosis for FQHC Patients

Martha Welman, Neighborhood Health, Alexandria, VA

PS5-11-12

Economic Impact of Adverse Event Management in HR+/HER2− Metastatic Breast Cancer: A Comparative Analysis of Datopotamab deruxtecan and standard of care in the Brazilian Private Healthcare System

Thiago Belchior de Oliveira, Daiichi Sankyo, São Paulo, Brazil

PS5-05-02

Real world data (RWD) outcome analysis of ESR1 mutation emergence in HR+/HER2- metastatic breast cancer through the continuum of standard of care hormonal therapy

Malvika Pillai, Tempus AI, Chicago, IL

PS5-11-14

Systemic Barriers to Breast Cancer Care in Conflict-Affected Syria

Ahmad Al-Bitar, Damascus University, Damascus, Syrian Arab Republic

PS5-05-21

Breast Cancer in Syria: An Epidemiological Analysis from the Country’s Main Cancer Center

Ahmad Al-Bitar, Damascus University, Damascus, Syrian Arab Republic

PS5-06-17

Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with breast cancer using blue dye alone: Results from a multicenter study in Public Hospitals in Brazil

Rafael Henrique Szymanski Machado, Hospital Federal da Lagoa, Rio de Janeiro, Brazil

PS5-06-25

Investigating association of comorbidities and race with all-cause mortality outcomes of PI3K inhibitor use in metastatic breast cancer (mBC)

Tahj S Morales, Penn State College of Medicine, Hershey, PA

PS5-04-08

Abemaciclib plus endocrine therapy in hr+/her2− advanced breast cancer: insights from an italian retrospective observational study

Elisabetta Munzone, Division of Medical Senology, European Institute of Oncology IRCCS, Milan, Italy

PS5-12-05

Cdk4/6 inhibitors in outpatient gynecological oncology: identification of implementation barriers and opportunities for improving their use in the practice

Mohamed Elessawy, UKSH, Kiel, Germany

PS5-04-18

Real-world patterns of trastuzumab deruxtecan discontinuation in metastatic breast cancer: insights from a single-center experience

Luca Licata, IRCCS San Raffaele Hospital, Milan, Italy

PS5-12-12

Internet use, access to care, and breast cancer screening among publicly insured women

Hanan Jalal Mohammad, University of Texas San Antonio School of Public Health, San Antonio, TX

PS5-04-19

70-gene signature high risk classification provides stronger prognostic value than histologic grade in hr+ her2- early breast cancer

Erin F Cobain, University of Michigan Medical School, Ann Arbor, MI

PS5-12-14

Between Hope and Hardship: Patient Perspectives on Treatment Cessation in Metastatic Breast Cancer in Syria

Ayla Kouli, Damascus University, Damascus, Syrian Arab Republic

PS5-04-21

Impact of Germline BCRA variants in the neoadjuvant treatment

Natalia Valdiviezo, Oncología Médica, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru

PS5-12-15

Outdoor ambient air pollution and breast cancer survival among Chinese patients: a multi-center analysis of 18553cases

Yuzhu Zhang, Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University,, Taizhou, China

PS5-12-26

Yoga in Breast Cancer Survivorship: Knowledge, Attitudes, <Perceived Benefits.

Prasenjit AH Chatterjee, MANIPAL HOSPITAL, KOLKATA, India

PS5-12-27

The impact of immediate contralateral breast symmetrization on body satisfaction among breast cancer survivors.

Andrea Cavalheiro Cubero, Department of Mastology, ABC School of Medicine, Santo André, Brazil

PS5-12-28

Human Development Index and Breast Cancer Prognosis in Chinese Women: A Multiregional Survival Analysis

Wanting Wang, School of artificial intelligence, Taizhou University, Taizhou, China

PS5-12-29

Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health

Anqi Yuan, Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University, Taizhou, China, Taizhou, China

PS5-12-30

Suicidal Ideation and the Role of Social Support Among Breast Cancer Patients in Syria

Ahmad Al-Bitar, Damascus University, Damascus, Syrian Arab Republic

PS5-04-22

Interventions to Improve Hope and Psychosocial Outcomes in Patients with Breast Cancer: A Systematic Review

Rachel L Hoover, Albany Medical College, Albany, NY

PS5-04-23

Patient priorities for breast cancer survivorship: a preliminary descriptive analysis of the health outcome goals that matter most to older adults breast cancer survivors

Dana E Giza, University of Texas Health Science Center, Houston, TX

PS5-04-25

A phase II trial of platelet-rich plasma for breast cancer patients with genitourinary syndrome of menopause

Melissa Curran, University of Miami Miller School of Medicine, Miami, FL

PS5-04-26

Tailored Support for Young Women with Breast Cancer: Survey-Informed Program Development and Peer-Based Intervention

Shari Goldfarb, MSKCC, New York City, NY

PS5-04-27

Quality of life in patients with advanced breast cancer (aBC) treated with ribociclib (RIB) in the real-world RIBANNA trial

Peter A Fasching, University Hospital Erlangen, Erlangen, Germany

PS5-04-09

Patient-reported measures of taxane-induced peripheral neuropathy (TIPN) and risk of dose reductions or worsening quality of life in Black women with breast cancer: analysis from ECOG-ACRIN EAZ171

Tarah J. Ballinger, Indiana University, Indianapolis, IN

PS5-03-05

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional safety analyses from the TROPION-Breast02 study

Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY